Micro-RNA-16 expression in paraffin-embedded specimen correlates with overall survival of T-lymphoblastic lymphoma/leukemia

Yanfeng Xi, Jing Li, Likun Zan, Jinfen Wang, Guoping Wang, Yi Ning

Research output: Contribution to journalArticle

Abstract

The diagnosis and prognosis of T-lymphoblastic lymphoma/leukemia represent a clinical challenge due to their relative rarity as well as their heterogeneous morphology and immunophenotype. In contrast to the significant progress in uncovering genetic lesions and prognostic factors for B-cell lineage lymphoid malignancies, prognostic markers that can predict clinical outcome of T-lymphoblastic lymphoma/leukemia remain to be discovered and validated. Recently, specific micro-RNAs have emerged as potential biomarkers for the diagnosis and prognosis of various types of tumor. Among them, miR-16 is known to play important roles in the development of hematological malignancies. Using quantitative real-time reverse transcription-polymerase chain reaction, we analyzed miR-16 expression level in archived formalin-fixed and paraffin-embedded diagnostic lymph node specimens from a total of 72 patients with T-lymphoblastic lymphoma/leukemia and for which clinical follow-up information was available. Although no statistically significant difference was evident in patients with T-lymphoblastic lymphoma/leukemia versus controls with reactive lymph nodes (P =.163), T-lymphoblastic lymphoma/leukemia patients with a greater than median expression level of miR-16 had a longer overall survival than patients with a less than median expression level. The overall 1-year survival rate was 50% for the high expression group but was 26.5% for the low expression group (P =.043). To our knowledge, we provide here the first evidence that the expression of a single micro-RNA, miR-16, is associated with clinical outcome of patients with T-lymphoblastic lymphoma/leukemia. Therefore, miR-16 may be considered as a potential prognostic marker for T-lymphoblastic lymphoma/leukemia.

Original languageEnglish (US)
Pages (from-to)1011-1016
Number of pages6
JournalHuman Pathology
Volume44
Issue number6
DOIs
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

MicroRNAs
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Paraffin
Survival
Lymph Nodes
Cell Lineage
Hematologic Neoplasms
Formaldehyde
Reverse Transcription
Neoplasms
B-Lymphocytes
Survival Rate
Biomarkers

Keywords

  • Lymphoma
  • miRNA-16
  • Survival and prognosis
  • T-LBL/ALL

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Micro-RNA-16 expression in paraffin-embedded specimen correlates with overall survival of T-lymphoblastic lymphoma/leukemia. / Xi, Yanfeng; Li, Jing; Zan, Likun; Wang, Jinfen; Wang, Guoping; Ning, Yi.

In: Human Pathology, Vol. 44, No. 6, 06.2013, p. 1011-1016.

Research output: Contribution to journalArticle

Xi, Yanfeng ; Li, Jing ; Zan, Likun ; Wang, Jinfen ; Wang, Guoping ; Ning, Yi. / Micro-RNA-16 expression in paraffin-embedded specimen correlates with overall survival of T-lymphoblastic lymphoma/leukemia. In: Human Pathology. 2013 ; Vol. 44, No. 6. pp. 1011-1016.
@article{aab91131940a49eebee9500a48d17f52,
title = "Micro-RNA-16 expression in paraffin-embedded specimen correlates with overall survival of T-lymphoblastic lymphoma/leukemia",
abstract = "The diagnosis and prognosis of T-lymphoblastic lymphoma/leukemia represent a clinical challenge due to their relative rarity as well as their heterogeneous morphology and immunophenotype. In contrast to the significant progress in uncovering genetic lesions and prognostic factors for B-cell lineage lymphoid malignancies, prognostic markers that can predict clinical outcome of T-lymphoblastic lymphoma/leukemia remain to be discovered and validated. Recently, specific micro-RNAs have emerged as potential biomarkers for the diagnosis and prognosis of various types of tumor. Among them, miR-16 is known to play important roles in the development of hematological malignancies. Using quantitative real-time reverse transcription-polymerase chain reaction, we analyzed miR-16 expression level in archived formalin-fixed and paraffin-embedded diagnostic lymph node specimens from a total of 72 patients with T-lymphoblastic lymphoma/leukemia and for which clinical follow-up information was available. Although no statistically significant difference was evident in patients with T-lymphoblastic lymphoma/leukemia versus controls with reactive lymph nodes (P =.163), T-lymphoblastic lymphoma/leukemia patients with a greater than median expression level of miR-16 had a longer overall survival than patients with a less than median expression level. The overall 1-year survival rate was 50{\%} for the high expression group but was 26.5{\%} for the low expression group (P =.043). To our knowledge, we provide here the first evidence that the expression of a single micro-RNA, miR-16, is associated with clinical outcome of patients with T-lymphoblastic lymphoma/leukemia. Therefore, miR-16 may be considered as a potential prognostic marker for T-lymphoblastic lymphoma/leukemia.",
keywords = "Lymphoma, miRNA-16, Survival and prognosis, T-LBL/ALL",
author = "Yanfeng Xi and Jing Li and Likun Zan and Jinfen Wang and Guoping Wang and Yi Ning",
year = "2013",
month = "6",
doi = "10.1016/j.humpath.2012.08.023",
language = "English (US)",
volume = "44",
pages = "1011--1016",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Micro-RNA-16 expression in paraffin-embedded specimen correlates with overall survival of T-lymphoblastic lymphoma/leukemia

AU - Xi, Yanfeng

AU - Li, Jing

AU - Zan, Likun

AU - Wang, Jinfen

AU - Wang, Guoping

AU - Ning, Yi

PY - 2013/6

Y1 - 2013/6

N2 - The diagnosis and prognosis of T-lymphoblastic lymphoma/leukemia represent a clinical challenge due to their relative rarity as well as their heterogeneous morphology and immunophenotype. In contrast to the significant progress in uncovering genetic lesions and prognostic factors for B-cell lineage lymphoid malignancies, prognostic markers that can predict clinical outcome of T-lymphoblastic lymphoma/leukemia remain to be discovered and validated. Recently, specific micro-RNAs have emerged as potential biomarkers for the diagnosis and prognosis of various types of tumor. Among them, miR-16 is known to play important roles in the development of hematological malignancies. Using quantitative real-time reverse transcription-polymerase chain reaction, we analyzed miR-16 expression level in archived formalin-fixed and paraffin-embedded diagnostic lymph node specimens from a total of 72 patients with T-lymphoblastic lymphoma/leukemia and for which clinical follow-up information was available. Although no statistically significant difference was evident in patients with T-lymphoblastic lymphoma/leukemia versus controls with reactive lymph nodes (P =.163), T-lymphoblastic lymphoma/leukemia patients with a greater than median expression level of miR-16 had a longer overall survival than patients with a less than median expression level. The overall 1-year survival rate was 50% for the high expression group but was 26.5% for the low expression group (P =.043). To our knowledge, we provide here the first evidence that the expression of a single micro-RNA, miR-16, is associated with clinical outcome of patients with T-lymphoblastic lymphoma/leukemia. Therefore, miR-16 may be considered as a potential prognostic marker for T-lymphoblastic lymphoma/leukemia.

AB - The diagnosis and prognosis of T-lymphoblastic lymphoma/leukemia represent a clinical challenge due to their relative rarity as well as their heterogeneous morphology and immunophenotype. In contrast to the significant progress in uncovering genetic lesions and prognostic factors for B-cell lineage lymphoid malignancies, prognostic markers that can predict clinical outcome of T-lymphoblastic lymphoma/leukemia remain to be discovered and validated. Recently, specific micro-RNAs have emerged as potential biomarkers for the diagnosis and prognosis of various types of tumor. Among them, miR-16 is known to play important roles in the development of hematological malignancies. Using quantitative real-time reverse transcription-polymerase chain reaction, we analyzed miR-16 expression level in archived formalin-fixed and paraffin-embedded diagnostic lymph node specimens from a total of 72 patients with T-lymphoblastic lymphoma/leukemia and for which clinical follow-up information was available. Although no statistically significant difference was evident in patients with T-lymphoblastic lymphoma/leukemia versus controls with reactive lymph nodes (P =.163), T-lymphoblastic lymphoma/leukemia patients with a greater than median expression level of miR-16 had a longer overall survival than patients with a less than median expression level. The overall 1-year survival rate was 50% for the high expression group but was 26.5% for the low expression group (P =.043). To our knowledge, we provide here the first evidence that the expression of a single micro-RNA, miR-16, is associated with clinical outcome of patients with T-lymphoblastic lymphoma/leukemia. Therefore, miR-16 may be considered as a potential prognostic marker for T-lymphoblastic lymphoma/leukemia.

KW - Lymphoma

KW - miRNA-16

KW - Survival and prognosis

KW - T-LBL/ALL

UR - http://www.scopus.com/inward/record.url?scp=84878112403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878112403&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2012.08.023

DO - 10.1016/j.humpath.2012.08.023

M3 - Article

C2 - 23260326

AN - SCOPUS:84878112403

VL - 44

SP - 1011

EP - 1016

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 6

ER -